<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699981</url>
  </required_header>
  <id_info>
    <org_study_id>COPROBLSE2</org_study_id>
    <nct_id>NCT04699981</nct_id>
  </id_info>
  <brief_title>Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?</brief_title>
  <acronym>CORPOBLSE2</acronym>
  <official_title>Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among Enterobacteriaceae, the production of beta-lactamases (ESBLs) is the leading cause of&#xD;
      multi-resistance. The first cases of ESBL-producing Enterobacteriaceae (E-ESBL) infections&#xD;
      were described in the 1980s and subsequently experienced worldwide dissemination.&#xD;
&#xD;
      Since the turn of the century, the prevalence of E-ESBL infections, especially among&#xD;
      Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) has increased&#xD;
      dramatically.&#xD;
&#xD;
      The emergence of multidrug-resistant Enterobacteriaceae is currently a real public health&#xD;
      problem. The European Antimicrobial Resistance Surveillance Network evaluated, among clinical&#xD;
      strains, the rate of resistance to 3rd generation cephalosporins (C3G) at 9.5% for E. coli&#xD;
      and 28% for K. pneumoniae. Numerous studies have shown that bacterial colonization is the&#xD;
      prerequisite for the occurrence of many infections.&#xD;
&#xD;
      However, the existence of prior colonization does not seem to be the only risk factor for the&#xD;
      occurrence of a secondary infection. Therefore, in patients with multidrug-resistant&#xD;
      Gram-negative bacillus gastrointestinal carriage there appear to be factors associated with&#xD;
      the onset of infection. Several studies have examined the risk factors associated with&#xD;
      E-ESBL-related infections in both community-based and healthcare-associated / nosocomial&#xD;
      infections. Two main risk factors seem to be associated with E-ESBL infections: prior&#xD;
      antibiotic therapy and the existence of invasive devices.&#xD;
&#xD;
      A recent study, carried out on 1288 patients and aimed at validating a predictive score for&#xD;
      the occurrence of ESBL-E bacteremia, demonstrated 5 factors associated with the appearance of&#xD;
      E-ESBL-linked bacteremia. These factors were: (i) a history of colonization / infection with&#xD;
      ESBL-E, (ii) age ≥ 43 years, (iii) recent hospitalization in a region with a high prevalence&#xD;
      of ESBL-E, (iv) antibiotic therapy ≥ 6 days in the previous 6 months and (v) the existence of&#xD;
      a chronic vascular access.&#xD;
&#xD;
      Recently, a retrospective case-control study conducted in the United States by Augustine et&#xD;
      al. Suggested that 5% of cases of bacteremia were related to ESBL-E.&#xD;
&#xD;
      Few studies have looked at risk factors for infection in patients known to be colonized by&#xD;
      the digestive system. In a retrospective case-control study, conducted outside the intensive&#xD;
      care unit and including pediatric and adult patients, the authors identified 2 factors&#xD;
      associated with the occurrence of Ec-ESBL infection in previously colonized patients. These&#xD;
      two factors were the prior use of antibiotics with β-lactam antibiotics and β-lactamase&#xD;
      inhibitor (s), and urinary catheterization.&#xD;
&#xD;
      In intensive care hospital patients, the occurrence of ESBL-producing enterobacteriaceae&#xD;
      infection appears to be a rare event, including in colonized patients.&#xD;
&#xD;
      The work of Ruppé et al. showed a direct link between relative fecal abundance of&#xD;
      EScher-producing Escherichia coli and prior antibiotic intake.&#xD;
&#xD;
      This work also demonstrated a link between the value of the relative fecal abundance in&#xD;
      Ec-ESBL and the occurrence of a urinary tract infection linked to the same clone. In&#xD;
      particular, the authors found that women with a low relative fecal abundance rate (≤ 0.1%)&#xD;
      had no risk of developing an Escherichia coli urinary tract infection. Conversely, the risk&#xD;
      increased with the relative fecal abundance of Escherichia coli, but with a positive&#xD;
      predictive value limited to 57% for relative fecal abundances between 10 and 100%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of EBLSE</measure>
    <time_frame>Day 60</time_frame>
    <description>This outcome corresponds to comparison of the relative fecal abundance (expressed as a percentage) of ESBL E and the microbiota in the 2 groups of patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Enterobacteria Infections</condition>
  <arm_group>
    <arm_group_label>Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)</intervention_name>
    <description>For patients included in the &quot;Control group&quot; on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.).</description>
    <arm_group_label>Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)</intervention_name>
    <description>A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of &quot;normal&quot; transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool.</description>
    <arm_group_label>Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (≥ 18 years old) hospitalized at the Paris Saint-Joseph Hospital Group&#xD;
             or in the intensive care unit of Avicenne hospital, Necker Enfants Malades hospital,&#xD;
             Center Sud Francilien, detected as a carrier of enterobacteriaceae in the digestive&#xD;
             system ESBL producers&#xD;
&#xD;
          -  Patient who had not had antibiotic treatment in the 3 weeks before inclusion&#xD;
&#xD;
          -  Patient affiliated to a health insurance plan&#xD;
&#xD;
          -  French-speaking patient&#xD;
&#xD;
          -  Patient living at home, in EHPAD or retirement home&#xD;
&#xD;
          -  Patient or Relative able to give free, informed and express consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known patient colonized rectally with ESBL-producing enterobacteria and subjected to&#xD;
             antibiotic pressure other than beta-lactams&#xD;
&#xD;
          -  Time to inclusion&gt; 24 hours after initiation of antibiotic therapy&#xD;
&#xD;
          -  Patient participating simultaneously in other intervention research that may interfere&#xD;
             with the objectives of the study&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient deprived of liberty&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit PILMIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit PILMIS, MD</last_name>
    <phone>144127820</phone>
    <phone_ext>+33</phone_ext>
    <email>bpilmis@ghpsj.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helene BEAUSSIER, PharmD, pHD</last_name>
    <phone>144127883</phone>
    <phone_ext>+33</phone_ext>
    <email>crc@ghpsj.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <state>Groupe Hospitalier Paris Saint-Joseph</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit PILMIS, MD</last_name>
      <phone>144127820</phone>
      <phone_ext>+33</phone_ext>
      <email>bpilmis@ghpsj.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants malades</name>
      <address>
        <city>Paris</city>
        <state>Groupe Hospitalier Paris Saint-Joseph</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire ROUZAUD, MD</last_name>
      <email>claire.rouzaud@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Claire ROUZAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Ralph Zahar, MD</last_name>
      <email>jean-ralph.zahar@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Ralph Zahar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud-Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier LECOINTE, MD</last_name>
      <email>didier.lecointe@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Didier LECOINTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004 Aug 21-27;364(9435):703-5.</citation>
    <PMID>15325835</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruyère R, Vigneron C, Bador J, Aho S, Toitot A, Quenot JP, Prin S, Charles PE. Significance of Prior Digestive Colonization With Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Patients With Ventilator-Associated Pneumonia. Crit Care Med. 2016 Apr;44(4):699-706. doi: 10.1097/CCM.0000000000001471.</citation>
    <PMID>26571186</PMID>
  </results_reference>
  <results_reference>
    <citation>Dubinsky-Pertzov B, Temkin E, Harbarth S, Fankhauser-Rodriguez C, Carevic B, Radovanovic I, Ris F, Kariv Y, Buchs NC, Schiffer E, Cohen Percia S, Nutman A, Fallach N, Klausner J, Carmeli Y; R-GNOSIS WP4 Study Group. Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal Surgery: A Prospective Cohort Study. Clin Infect Dis. 2019 May 2;68(10):1699-1704. doi: 10.1093/cid/ciy768.</citation>
    <PMID>30204851</PMID>
  </results_reference>
  <results_reference>
    <citation>Zahar JR, Lesprit P, Ruckly S, Eden A, Hikombo H, Bernard L, Harbarth S, Timsit JF, Brun-Buisson C; BacterCom Study Group. Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2017 Jan;49(1):67-73. doi: 10.1016/j.ijantimicag.2016.09.032. Epub 2016 Nov 16. Erratum in: Int J Antimicrob Agents. 2017 Apr;49(4):480-481.</citation>
    <PMID>27890442</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012 Jan 15;54(2):167-74. doi: 10.1093/cid/cir790. Epub 2011 Nov 4.</citation>
    <PMID>22057701</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH, Milstone AM, Massey CJ, Tamma PD; Antibacterial Resistance Leadership Group. A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism. Clin Infect Dis. 2016 Oct 1;63(7):896-903. doi: 10.1093/cid/ciw425. Epub 2016 Jun 28.</citation>
    <PMID>27358356</PMID>
  </results_reference>
  <results_reference>
    <citation>Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates. Infect Control Hosp Epidemiol. 2017 Mar;38(3):266-272. doi: 10.1017/ice.2016.292. Epub 2016 Dec 19.</citation>
    <PMID>27989244</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

